Twist Bioscience (TWST) Cash from Operations (2017 - 2026)

Twist Bioscience (TWST) has reported Cash from Operations for 10 consecutive years, with $1.1 million the latest figure, recorded in Q2 2026.

• On a quarterly basis, Cash from Operations rose 179.64% year-over-year to $1.1 million in Q2 2026; TTM through Jun 2026 was -$53.1 million, a 3.79% decrease from a year earlier, with the FY2025 full-year figure at -$47.6 million, up 25.69% from the prior year.
• Cash from Operations was $1.1 million for Q2 2026 at Twist Bioscience, up from -$17.6 million in the prior quarter.
• Over five years, Cash from Operations peaked at $1.1 million in Q2 2026 and troughed at -$54.1 million in Q4 2022.
• A 5-year average of -$20.7 million and a median of -$20.1 million in 2023 frame the typical range for Cash from Operations.
• Across the five-year window, Cash from Operations slumped 1534.1% in 2023 and surged 179.64% in 2026, its largest moves.
• Over 5 years, Cash from Operations stood at -$54.1 million in 2022, then jumped by 57.51% to -$23.0 million in 2023, then advanced by 6.73% to -$21.4 million in 2024, then dropped by 15.8% to -$24.8 million in 2025, then soared by 104.49% to $1.1 million in 2026.
• The last three Cash from Operations figures came in at $1.1 million (Q2 2026), -$17.6 million (Q1 2026), and -$24.8 million (Q4 2025), per Business Quant data.